UniQure is expected to report four-year results before the end of September for AMT-130, its gene therapy for Huntington’s disease, according to a STAT+ preview. The trial has already reported three-year data, with high-dose treatment in 12 patients showing slowed progression of Huntington’s by 75% versus matched participants from an external natural history study. The upcoming longer-term analysis is likely to focus on durability of clinical effects and how the safety profile evolves over time. In gene therapy trials, multi-year follow-up also becomes central to assessing whether early signals persist and whether any late-emerging risks appear. For the biotech ecosystem, the report acts as a major valuation and decision checkpoint because the Huntington’s space is competitive and investors increasingly expect both effect size and durability. The four-year timing also means sponsors across neurodegeneration can calibrate expectations for how gene-delivered programs are evaluated beyond initial windows.